

April 18, 2018

**For Immediate Release**

Company name Otsuka Holdings Co., Ltd.  
Representative Tatsuo Higuchi  
President and Representative Director, CEO  
Code number 4578 First Section , Tokyo Stock Exchange  
Inquiries Yuji Kogure  
Director, Investors Relations Department

**REXULTI<sup>®</sup> Tablets, a New Antipsychotic Drug, Launched in Japan**

Otsuka Pharmaceutical Co., Ltd. today announces the launch in Japan of REXULTI<sup>®</sup> Tablets (chemical name is brexpiprazole) in 1 mg and 2 mg tablets for the treatment of patients with schizophrenia. REXULTI is already available to patients in the U.S., Canada and Australia.

Based on the efficacy of REXULTI in the treatment of schizophrenia, it is included on the Japanese National Health Insurance Drug Price List as of April 18.

Brexpiprazole, a novel compound discovered by Otsuka, is a serotonin-dopamine activity modulator (SDAM, a new mechanism of action) that acts as a partial agonist at serotonin 5-HT<sub>1A</sub> and dopamine D<sub>2</sub> receptors, and an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Brexpiprazole exhibits high affinity for these receptors as well as for noradrenaline alpha<sub>1B/2C</sub> receptors.

REXULTI Tablets will be marketed to healthcare institutions across Japan starting from today.